Unraveling the mystery surrounding post-acute sequelae of COVID-19
RK Ramakrishnan, T Kashour, Q Hamid… - Frontiers in …, 2021 - frontiersin.org
More than one year since its emergence, corona virus disease 2019 (COVID-19) is still
looming large with a paucity of treatment options. To add to this burden, a sizeable subset of …
looming large with a paucity of treatment options. To add to this burden, a sizeable subset of …
Metabolism of immune cells in cancer
RD Leone, JD Powell - Nature reviews cancer, 2020 - nature.com
Through the successes of checkpoint blockade and adoptive cellular therapy,
immunotherapy has become an established treatment modality for cancer. Cellular …
immunotherapy has become an established treatment modality for cancer. Cellular …
Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients
HY Zheng, M Zhang, CX Yang, N Zhang… - Cellular & molecular …, 2020 - nature.com
The novel contagious primary atypical pneumonia epidemic, which broke out in Wuhan,
China, in December 2019, is now formally called Coronavirus Disease 2019 (COVID-19) …
China, in December 2019, is now formally called Coronavirus Disease 2019 (COVID-19) …
[HTML][HTML] The laboratory tests and host immunity of COVID-19 patients with different severity of illness
F Wang, H Hou, Y Luo, G Tang, S Wu, M Huang, W Liu… - JCI insight, 2020 - ncbi.nlm.nih.gov
BACKGROUND The coronavirus disease 2019 (COVID-19), infected by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak …
Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
D Gumber, LD Wang - EBioMedicine, 2022 - thelancet.com
Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …
enormous potential, demonstrating impressive antitumor activity in the treatment of …
Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
V Furer, D Zisman, A Kibari, D Rimar, Y Paran… - …, 2021 - academic.oup.com
Objectives As global vaccination campaigns against COVID-19 disease commence, vaccine
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
T‐cell responses and therapies against SARS‐CoV‐2 infection
Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2, a novel
coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related …
coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related …
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
AR Lim, WK Rathmell, JC Rathmell - Elife, 2020 - elifesciences.org
Breakthroughs in anti-tumor immunity have led to unprecedented advances in
immunotherapy, yet it is now clear that the tumor microenvironment (TME) restrains …
immunotherapy, yet it is now clear that the tumor microenvironment (TME) restrains …
Lean NAFLD: a distinct entity shaped by differential metabolic adaptation
Conclusions This study demonstrates that E. multilocularis can induce T‐cell exhaustion
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …
[HTML][HTML] The PD-1/PD-L1 axis and virus infections: a delicate balance
G Schönrich, MJ Raftery - Frontiers in cellular and infection …, 2019 - frontiersin.org
Programmed cell death protein (PD-1) and its ligands play a fundamental role in the evasion
of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 …
of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 …